|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7700 EUR | +1.05% |
|
-3.02% | -19.79% |
| 05-22 | Transgene SA Announces Board Appointments | CI |
| 04-13 | Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- TNG Stock
- Consensus Transgene
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
